Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

LEARNING OBJECTIVES

• Evaluate various clinical, biological and patient-related factors, such as age, site or bulk of disease, performance status, comorbid conditions and receipt of prior therapy, and use this information to personalize treatment recommendations for newly diagnosed extensive-stage small cell lung cancer (ES-SCLC).
• Review long-term data supporting the use of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy as first-line therapy for patients with ES-SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
• Appreciate the biological rationale for the evaluation of maintenance treatment after chemoimmunotherapy induction, and recognize available research establishing the benefit of this approach.
• Recognize adverse events associated with available first-line and maintenance therapies for ES-SCLC, and develop strategies to manage and mitigate these complications.
• Recall the design of ongoing clinical trials evaluating novel first-line and maintenance strategies for ES-SCLC, and as appropriate, counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/FirstLineTherapySCLC2025/2/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Axiom Healthcare Strategies, Bayer HealthCare Pharmaceuticals, BeOne, BerGenBio ASA, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grid Therapeutics, Guardant Health, IO Biotech, iTeos Therapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncocyte, Pfizer Inc, PharmaMar, Puma Biotechnology Inc, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Summit Therapeutics, SystImmune Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Lilly; Data and Safety Monitoring Boards/Committees: Incyte Corporation, Novartis, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Takeda Pharmaceuticals USA Inc; Honoraria: Amgen Inc, Daiichi Sankyo Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc; Stock OPTIONS — Private Companies: Inspirna, Nucleai, Sonnet BioTherapeutics Holdings Inc; Travel: Amgen Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationships: University of Pennsylvania.

Anne Chiang, MD, PhD
Associate Professor
Yale University School of Medicine
Associate Cancer Center Director
Clinical Initiatives
Yale Cancer Center
New Haven, Connecticut

Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Zai Lab; Consulting Agreements: AbbVie Inc, Merck; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Zai Lab; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Honoraria for Lectures: Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Genentech, a member of the Roche Group, and Jazz Pharmaceuticals Inc.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Byers LA et al. Safety and efficacy of ABBV-706, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in R/R SCLC. World Conference on Lung Cancer 2025;Abstract OA06.04.

Cheng Y et al. Phase II study of the efficacy and safety of BNT327/PM8002 plus systemic chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC). European Lung Cancer Congress 2025;Abstract 302P.

Cheng Y et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer. JAMA 2022;328(12):1223-32. Abstract

Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract

Kalinka E et al. BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study. ESMO 2024;Abstract 1786O.

Paulson KG et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study. Lancet Oncol 2025;26(10):1300-11. Abstract

Paz-Ares L et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial. Lancet 2025;405(10495):2129-43. Abstract

Paz-Ares LG et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. ASCO 2025;Abstract 8006.

Paz-Ares L et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7(2):100408. Abstract

Paz-Ares LG et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. ASCO 2019;Abstract 8506.

Rudin CM et al. SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2024;42(3):324-35. Abstract

Rudin CM et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020;38(21):2369-79. Abstract

Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(6):739-47. Abstract

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of colorectal cancer.

LEARNING OBJECTIVES

• Develop an understanding of the clinical relevance of circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in colorectal cancer (CRC), and recognize the rationale for its use in detecting molecular residual disease (MRD) in patients with this disease.
• Outline optimal approaches for ctDNA-based assessment of MRD, and determine the appropriate timing of and platform for testing ctDNA status in patients with CRC.
• Appreciate published datasets documenting the clinical utility of ctDNA testing in risk stratification, surveillance and treatment decision-making for patients with CRC, and consider the current and potential role of this strategy in personalizing treatment recommendations for localized and advanced disease.
• Recall ongoing efforts examining ctDNA-based assays for clinical decision-making in different CRC settings, and appropriately refer patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/CRCThinkTank2025/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Stacey A Cohen, MD
Professor
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington

Advisory Committees: AbbVie Inc, Agenus Inc, Caris Life Sciences, DoMore Diagnostics, Exact Sciences Corporation, Guardant Health, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: GSK.

Arvind Dasari, MD, MS
Professor
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committees: Agenus Inc, Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Crinetics Pharmaceuticals, Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, RayzeBio Inc, Taiho Oncology Inc, Xencor.

Christopher Lieu, MD
Professor of Medicine
Associate Director for Clinical Research
Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Consulting Agreements (to Institution): Pfizer Inc; Contracted Research (All to Institution): Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Natera Inc.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Cohen

Cohen SA et al. Practical recommendations for using ctDNA in clinical decision making. Nature 2023;619(7969):259-68. Abstract

Dasari A et al. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. ASCO 2023;Abstract 3522.

Dasari A et al. ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 2020;17(12):757-70. Abstract

Gianni C et al. Cell-free DNA fragmentomics: A promising biomarker for diagnosis, prognosis and prediction of response in breast cancer. Int J Mol Sci 2022;23(22):14197. Abstract

Kasi PM et al. Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial. Gastrointestinal Cancers Symposium 2024;Abstract 117.

Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract

Kotaka M et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. Gastrointestinal Cancers Symposium 2022;Abstract 9.

Maddalena G et al. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. Gastrointestinal Cancers Symposium 2024;Abstract 27.

Nakamura Y et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 2024;30(11):3272-83. Abstract

Parikh AR et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res 2021;27(20):5586-94. Abstract

Rolfo C, Russo A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 2020;17(9):523-4. Abstract

Shah PK et al. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Gastrointestinal Cancers Symposium 2025;Abstract 15.

Wan JCM et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17(4):223-38. Abstract

Dr Lieu

André T et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33(35):4176-87. Abstract

Bando H et al. A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study. Gastrointestinal Cancers Symposium 2025;Abstract LBA22.

Felder S et al. Correlation of mid-chemoradiation ctDNA results and clinical complete response to total neoadjuvant therapy (TNT) for locally advanced rectal adenocarcinoma. Gastrointestinal Cancers Symposium 2025;Abstract 263.

LaPelusa MB et al. Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer. ASCO 2024;Abstract 3612.

Mögele T et al. Circulating tumor DNA for prediction of complete pathological response to neoadjuvant radiochemotherapy in locally advanced rectal cancer (NEORECT trial). Cancers (Basel) 2024;16(24):4173. Abstract

Naidoo M et al. ctDNA and adjuvant therapy for colorectal cancer: Time to re-invent our treatment paradigm. Cancers (Basel) 2021;13(2):346. Abstract

Nowak JA et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. Gastrointestinal Cancers Symposium 2025;Abstract LBA14.

Sargent DJ et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009;27(12):1948-55. Abstract

Shah PK et al. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Gastrointestinal Cancers Symposium 2025;Abstract 15.

Tie J et al. ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG). ESMO 2025;Abstract LBA9.

Tie J et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. ASCO 2022;Abstract LBA100.

Dr Casari

Ciardiello D et al. Targeting KRASG12C in colorectal cancer: The beginning of a new era. ESMO Open 2023;8(1). Abstract

Cremolini C et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: A phase 2 single-arm clinical trial. JAMA Oncol 2019;5(3):343-50. Abstract

Dasari NA et al. Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance. ESMO GI 2025;Abstract 2O.

Garralda E et al. Broad utility of ultrasensitive analysis of ctDNA dynamics across solid tumors treated with immunotherapy. Clin Cancer Res 2026;32(2):333-49. Abstract

Kataoka K et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol 2024;35(11):1015-25. Abstract

McGranahan N et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015;7(283):283ra54. Abstract

Nakamura Y et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res 2024;30(19):4377-87. Abstract

Parikh AR et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin Cancer Res 2020;26(8):1877-85. Abstract

Parseghian CM et al. Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge. Ann Oncol 2019;30(2):243-9. Abstract

Sartore-Bianchi A et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. ASCO 2021;Abstract 3506.

Strickler JH et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov 2018;8(2):164-73. Abstract

Syeda MM et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study. Lancet Oncol 2021;22(3):370-80. Abstract

Zaanan A et al. Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study. J Natl Cancer Inst 2025;117(11):2362-71. Abstract

Faculty

TARGET AUDIENCE
This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

LEARNING OBJECTIVES

• Describe cereblon’s function in multiple myeloma (MM) formation and growth and its role in the degradation of key oncogenic proteins in order to better understand the rationale for the development of cereblon E3 ligase modulators (CELMoDs).
• Review the mechanism of action and unique characteristics of the CELMoDs under development for MM, and appreciate the similarities and differences between these therapies and currently approved immunomodulatory agents.
• Evaluate published efficacy and safety findings with CELMoDs in the advanced stages of development to prepare for the potential clinical availability of these agents for patients with relapsed/refractory (R/R) MM.
• Assess the biological rationale for combining CELMoDs with other agents commonly administered to patients with MM, and recognize available and emerging research findings with various combination approaches.
• Appreciate the frequency and severity of various therapy-related adverse events encountered by patients undergoing treatment with CELMoDs, and use this knowledge to identify, manage and mitigate resultant side effects.
• Consider the rationale for and designs of ongoing clinical trials evaluating CELMoDs for newly diagnosed and R/R MM, and counsel appropriately selected patients about the potential benefits of study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/InsideTheIssue2025/CELMoDsMM/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Natalie S Callander, MD
Professor of Medicine
Director, Myeloma Clinical and Cellular Therapy Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

No relevant financial relationships to disclose.

Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Bristol Myers Squibb. 

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here to identify further areas for study.

Byun JM et al. Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1. ASH 2025;Abstract 5835.

Hartley-Brown MA et al. Mezigdomide-A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024 Mar 15;16(6):1166. Abstract

Korst CLBM et al. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): A multicentre, single arm, phase 2 trial. Lancet Haematol 2026;13(1):e30-40. Abstract

Landgren O et al. A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The ReKinDLE study. ASH 2025;Abstract 251.

Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract

Merz L et al. The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. ASH 2025;Abstract 1033.

Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: STOMP phase 1 results. ASH 2025;Abstract 4010.

Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.

Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.

Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.

Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract

Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract

Suvannasankha A et al. Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial. ASH 2025;Abstract 100.

van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.

van de Donk NWCJ et al. The role of CELMoD agents in multiple myeloma. Onco Targets Ther 2025;18:921-33. Abstract

White D et al. Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. ASCO 2025;Abstract 7532.

Faculty

TARGET AUDIENCE
This program is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the diagnosis and treatment of gynecologic cancers.

LEARNING OBJECTIVES

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and as appropriate, counsel patients regarding personalized treatment recommendations.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates.
• Appreciate available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the potential role of this novel therapeutic strategy.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other local or systemic therapies for cervical cancer (CC), and effectively integrate immune checkpoint inhibition into the care of patients with this disease.
• Review published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing gynecologic cancers, and consider the role of various approaches in the care of patients with these diseases.
• Describe the scientific justification for, published research data with and current research studies of novel agents and strategies for OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PostESMO25/Gyn/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Advisory Committees: AbbVie Inc, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc, Whitehawk Therapeutics; Nonrelevant Financial Relationships: UpToDate.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aghajanian C et al. Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025. ESMO 2025;Abstract LBA44.

Akıllı H et al. First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. ESMO 2025;Abstract 1114P.

Barretina Ginesta MP et al. Final overall survival (OS) results from the randomized double-blind phase III AtTEND/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. ESMO 2025;Abstract LBA39.

Cibula D et al. Phase 3, randomized, double-blind, placebo (Pbo)-controlled ENGOT-ov43/GOG-3036/KEYLYNK-001 study of 1L chemotherapy (CT) ± pembrolizumab (Pembro) then maintenance (Maint) pembro ± olaparib (Ola) for advanced BRCA-nonmutated epithelial ovarian cancer (EOC): Analysis by HRD status. ESMO 2025; Abstract 1071P.

Clamp AR et al. ICON8B: GCIG phase III randomized trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk Stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis. ESMO 2025;Abstract 1064O.

Colombo N et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study. ESMO 2025;Abstract LBA3.

Denys H et al. Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWIST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis. ESMO 2025;Abstract 1070P.

Eminowicz G et al. GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). ESMO 2025;Abstract 1221TiP.

Gaba Garcia L et al. Neoadjuvant dostarlimab in mismatch repair deficient (MMRd) stage II-III endometrioid endometrial cancer (EC): The GEICO137-E/NADIA study. ESMO 2025;Abstract 1224TiP.

González-Martín A et al. An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01). ESMO 2025;Abstract 127TiP.

Kim SI et al. First-line niraparib maintenance therapy in BRCA wild-type, low-risk advanced ovarian cancer: The POLO trial. ESMO 2025;Abstract 1084P.

Lee J-Y et al. Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. ESMO 2025;Abstract 145P.

Li N et al. Fuzuloparib (FZPL) monotherapy or in combination with apatinib as first-line maintenance therapy in advanced ovarian cancer: Final analysis of the FZOCUS-1 trial. ESMO 2025;Abstract 1063O.

Makker V et al. Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775. ESMO 2025;Abstract 1119P.

Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.

Moore KN et al. FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab impact niraparib tolerability, exposure, or dose modification? ESMO 2025;Abstract 1101P.

Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract

Powell MA et al. Post-hoc survival outcomes based on initial and subsequent treatment in patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. ESMO 2025;Abstract 1113P.

Ray-Coquard IL. Combining pembrolizumab plus weekly paclitaxel +/- bevacizumab for platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract Discussant.

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

Slomovitz BM et al. A randomized phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY Endometrial 01/GOG-3098/ENGOT-EN24. ESMO 2025;Abstract 1223TiP.

Westin S et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial. ESMO 2025;Abstract 1117P.

Wu X et al. Phase III study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer. ESMO 2025;Abstract LBA38.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

LEARNING OBJECTIVES

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory multiple myeloma (MM).
• Evaluate the biological rationale for and published research with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and identify patients for whom this novel approach should be considered or recommended.
• Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom therapy with one of these novel agents would be appropriate.
• Review recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the current clinical role of this form of treatment.
• Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and counsel appropriate patients about participation in clinical trials.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 0.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CE ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/ASHRRMM25/Micro/2/Video and evaluation ResearchToPractice.com/ASHRRMM25/Micro/2/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Sagar Lonial, MD, FACP, FASCO
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from GSK.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Lonial S et al. Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments. ASH 2025;Abstract 12045.

Mateos M-V et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3. ASH 2025;Abstract LBA-6.

Quach H et al. Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. ASH 2025;Abstract 7278.

Sim S et al. Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14). ASH 2025;Abstract 7320.

Usmani S et al. Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the phase 1 DREAMM-9 study. ASH 2025;Abstract 13646.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

• Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, including for patients who experience biochemical recurrence after local therapy, and apply this information in the discussion of nonresearch treatment options.
• Assess the available research database with PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 0.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/PostESMO25/Micro/Prostate/2/Video and evaluation ResearchToPractice.com/PostESMO25/Micro/Prostate/2/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Rana R McKay, MD, FASCO
Professor of Medicine, Urology, and Radiation Medicine and Applied Sciences
Associate Director, Clinical Research
Co-Lead, Genitourinary Program
Moores Cancer Center
University of California San Diego
San Diego, California

Advisor/Consultant: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Johnson & Johnson, Lilly, Merck, Myovant Sciences, Neomorph, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Institutional Research Funding: Artera, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Oncternal Therapeutics, Tempus.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Natera Inc.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Aggarwal R et al. Final results from PRESTO: A phase III open-label study of combined androgen blockade in patients (pts) with high-risk biochemically relapsed prostate cancer (BRPC) (AFT-19). ESMO 2025;Abstract LBA88.

Azad AA et al. First interim efficacy analysis of the phase I/II PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC). ESMO 2025;Abstract 2384MO.

Galceran JC et al. Time to response with talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2. ESMO 2025;Abstract 2428P.

Shore ND et al. EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer. ESMO 2025;Abstract LBA87.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of squamous cell carcinoma of the anal canal.

LEARNING OBJECTIVES

• Appreciate the incidence, etiology and clinical and biological characteristics of squamous cell carcinoma of the anal canal (SCAC).
• Consider published research guiding the selection and sequencing of therapy for SCAC to facilitate optimal treatment and long-term outcomes for patients.
• Evaluate the scientific rationale for evaluating immune checkpoint inhibitors for advanced SCAC, and appreciate available research findings with anti-PD-1/PD-L1 antibody monotherapy for patients with relapsed/refractory disease.
• Assess recently presented research with chemotherapy in combination with anti-PD-1 antibody therapy as first-line treatment for advanced SCAC, and identify patients potentially eligible for this novel treatment approach.
• Review novel agents and strategies under clinical development for the treatment of SCAC, and appropriately refer eligible patients for trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 0.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodaySCCAnal25/Video and evaluation ResearchToPractice.com/OncologyTodaySCCAnal25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Marwan Fakih, MD
Professor, Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Director in Clinical Research
Associate Director for Clinical Sciences
Medical Director, Briskin Center for Clinical Research
Division Head, GI Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California

Advisory Committees: Genentech, a member of the Roche Group, Janssen Research and Development, Merus, Mirati Therapeutics Inc, Tempus, Xilio Therapeutics; Consulting Agreements: AbbVie Inc, Adagene, Bristol Myers Squibb, Delcath Systems Inc, Iterion Therapeutics, Merck, Microbial Machines, Mirati Therapeutics Inc, Revolution Medicines, Summit Therapeutics, Taiho Oncology Inc, Totus Medicines; Contracted Research: Agenus Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Incyte Corporation.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Fakih M et al. POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC). ASCO 2025; Abstract 3525.

Garg A et al. Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035. J Natl Cancer Inst 2024;116(9):1508-12. Abstract

Kim S et al. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): A randomised, non-comparative, phase 2 study. Lancet Oncol 2024;25(4):518-28. Abstract

Marabelle A et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7(5):446-54. Abstract

Morris V et al. NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal. ESMO GI 2023;Abstract O-12.

Morris VK et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(4):446-53. Abstract

Rao S et al. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): A global, phase 3 randomised controlled trial. Lancet 2025;405(10495):2144-52. Abstract

Rao S et al. Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC). ESMO Immuno-Oncology Congress 2025;Abstract 123MO.

Rao S et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7(4). Abstract

Rao S et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020;38(22):2510-8. Abstract

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of squamous cell carcinoma of the anal canal.

LEARNING OBJECTIVES

• Appreciate the incidence, etiology and clinical and biological characteristics of squamous cell carcinoma of the anal canal (SCAC).
• Consider published research guiding the selection and sequencing of therapy for SCAC to facilitate optimal treatment and long-term outcomes for patients.
• Evaluate the scientific rationale for evaluating immune checkpoint inhibitors for advanced SCAC, and appreciate available research findings with anti-PD-1/PD-L1 antibody monotherapy for patients with relapsed/refractory disease.
• Assess recently presented research with chemotherapy in combination with anti-PD-1 antibody therapy as first-line treatment for advanced SCAC, and identify patients potentially eligible for this novel treatment approach.
• Review novel agents and strategies under clinical development for the treatment of SCAC, and appropriately refer eligible patients for trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Lecture: ResearchToPractice.com/OncologyTodaySCCAnal25/Presentation and evaluation ResearchToPractice.com/OncologyTodaySCCAnal25/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Marwan Fakih, MD
Professor, Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Director in Clinical Research
Associate Director for Clinical Sciences
Medical Director, Briskin Center for Clinical Research
Division Head, GI Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California

Advisory Committees: Genentech, a member of the Roche Group, Janssen Research and Development, Merus, Mirati Therapeutics Inc, Tempus, Xilio Therapeutics; Consulting Agreements: AbbVie Inc, Adagene, Bristol Myers Squibb, Delcath Systems Inc, Iterion Therapeutics, Merck, Microbial Machines, Mirati Therapeutics Inc, Revolution Medicines, Summit Therapeutics, Taiho Oncology Inc, Totus Medicines; Contracted Research: Agenus Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Incyte Corporation.

Release date: February 2026
Expiration date: February 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Fakih M et al. POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC). ASCO 2025; Abstract 3525.

Garg A et al. Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035. J Natl Cancer Inst 2024;116(9):1508-12. Abstract

Kim S et al. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): A randomised, non-comparative, phase 2 study. Lancet Oncol 2024;25(4):518-28. Abstract

Marabelle A et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7(5):446-54. Abstract

Morris V et al. NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal. ESMO GI 2023;Abstract O-12.

Morris VK et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(4):446-53. Abstract

Rao S et al. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): A global, phase 3 randomised controlled trial. Lancet 2025;405(10495):2144-52. Abstract

Rao S et al. Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC). ESMO Immuno-Oncology Congress 2025;Abstract 123MO.

Rao S et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7(4). Abstract

Rao S et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020;38(22):2510-8. Abstract

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer.

LEARNING OBJECTIVES

• Understand the structural components and mechanism of action of novel antibody-drug conjugates (ADCs) under investigation in ovarian cancer (OC).
• Appreciate the incidence of cadherin-6 expression in OC, and consider available research findings with and the potential role of novel ADCs targeting this newly emerging biomarker.
• Recognize the rationale for targeting folate receptor alpha in OC, and discern how novel ADCs directed at this target may have a future role in treatment.
• Compare and contrast the toxicities associated with novel ADCs under development for patients with OC, and appreciate supportive management strategies available to minimize or ameliorate these side effects.
• Recall the design of ongoing clinical trials evaluating novel ADCs for OC, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayADCsOvarian25/Video and evaluation ResearchToPractice.com/OncologyTodayADCsOvarian25/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayADCsOvarian25/Presentation and evaluation ResearchToPractice.com/OncologyTodayADCsOvarian25/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Kathleen N Moore, MD, MS
Deputy Director and Director, Phase 1 Clinical Trials
Fred and Pamela Buffett Cancer Center at the University of Nebraska
Omaha, Nebraska

Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Daiichi Sankyo Inc and Merck.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Alvarez Secord A et al. Final analysis of the single-arm phase II PICCOLO trial of mirvetuximab soravtansine-gynx (MIRV) in folate receptor alpha (FRα)-positive, third-line and later (3L+), recurrent platinum-sensitive ovarian cancer (PSOC). ESMO Gynecological Cancers Congress 2025;Abstract 76MO.

Coleman RL et al. Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis. ASCO 2025;Abstract 5579.

Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract

Dum D et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors. ESMO 2022;Abstract 83P.

Lee D et al. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers. ESMO 2024;Abstract 765P.

Lee EK et al. (ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study. SGO 2025;Abstract.

Lee EK et al. A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. ESMO 2024;Abstract 719MO.

Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.

Martin LP et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 2017;147(2):402-7. Abstract

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Moore KN et al. Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study. ESMO Gynecological Cancers Congress 2025;Abstract 77MO.

Moore KN et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract LBA04.

Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract

Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. ESMO 2023;Abstract 745MO.

Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.

Oaknin A et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase 2 TROPION-PanTumor03 study. ESMO 2024;Abstract 714MO.

Petersen ME et al. Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates. Mol Cancer Ther 2024;23(5):606-18. Abstract

Rao Q et al. JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies. ESMO 2024;Abstract 759P.

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

Ray-Coquard IL et al. Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC). ESMO 2025;Abstract 1067P.

Schram A et al. Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation. SGO 2024;Abstract LBA26.

Shu J et al. IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study. ESMO 2024;Abstract 720MO.

Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. Abstract

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

Tew WP et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2022;40(33):3878-81. Abstract

Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. ESMO 2024;Abstract 715MO.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer.

LEARNING OBJECTIVES

• Understand the structural components and mechanism of action of novel antibody-drug conjugates (ADCs) under investigation in ovarian cancer (OC).
• Appreciate the incidence of cadherin-6 expression in OC, and consider available research findings with and the potential role of novel ADCs targeting this newly emerging biomarker.
• Recognize the rationale for targeting folate receptor alpha in OC, and discern how novel ADCs directed at this target may have a future role in treatment.
• Compare and contrast the toxicities associated with novel ADCs under development for patients with OC, and appreciate supportive management strategies available to minimize or ameliorate these side effects.
• Recall the design of ongoing clinical trials evaluating novel ADCs for OC, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayADCsOvarian25/Video and evaluation ResearchToPractice.com/OncologyTodayADCsOvarian25/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayADCsOvarian25/Presentation and evaluation ResearchToPractice.com/OncologyTodayADCsOvarian25/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Kathleen N Moore, MD, MS
Deputy Director and Director, Phase 1 Clinical Trials
Fred and Pamela Buffett Cancer Center at the University of Nebraska
Omaha, Nebraska

Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, Mersana Therapeutics Inc; Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, GSK, ImmunoGen Inc, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Whitehawk Therapeutics, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Accent Therapeutics, Advaxis Inc, Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, Immunocore, Iovance Biotherapeutics, Regeneron Pharmaceuticals Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics; Nonrelevant Financial Relationships: ASCO, GOG Partners, NRG Oncology.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Daiichi Sankyo Inc and Merck.

Release date: February 2026
Expiration date: February 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Alvarez Secord A et al. Final analysis of the single-arm phase II PICCOLO trial of mirvetuximab soravtansine-gynx (MIRV) in folate receptor alpha (FRα)-positive, third-line and later (3L+), recurrent platinum-sensitive ovarian cancer (PSOC). ESMO Gynecological Cancers Congress 2025;Abstract 76MO.

Coleman RL et al. Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis. ASCO 2025;Abstract 5579.

Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract

Dum D et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors. ESMO 2022;Abstract 83P.

Lee D et al. HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers. ESMO 2024;Abstract 765P.

Lee EK et al. (ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study. SGO 2025;Abstract.

Lee EK et al. A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. ESMO 2024;Abstract 719MO.

Makker V et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 1 final analysis. ESMO 2025;Abstract 957P.

Martin LP et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 2017;147(2):402-7. Abstract

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Moore KN et al. Raludotatug deruxtecan (R-DXd) monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): Subgroup analysis of a phase I study. ESMO Gynecological Cancers Congress 2025;Abstract 77MO.

Moore KN et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract LBA04.

Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract

Moore KN et al. Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study. ESMO 2023;Abstract 745MO.

Oaknin A et al. First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. ESMO 2025;Abstract 1065MO.

Oaknin A et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase 2 TROPION-PanTumor03 study. ESMO 2024;Abstract 714MO.

Petersen ME et al. Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates. Mol Cancer Ther 2024;23(5):606-18. Abstract

Rao Q et al. JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies. ESMO 2024;Abstract 759P.

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

Ray-Coquard IL et al. Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC). ESMO 2025;Abstract 1067P.

Schram A et al. Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation. SGO 2024;Abstract LBA26.

Shu J et al. IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study. ESMO 2024;Abstract 720MO.

Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. Abstract

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract

Tew WP et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2022;40(33):3878-81. Abstract

Wang D et al. Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. ESMO 2024;Abstract 715MO.